Evidence map›Paper›PMID 25341890›Full record

ArticleJournal of the American Heart Association2014

Anti-remodeling and anti-fibrotic effects of the neuregulin-1β glial growth factor 2 in a large animal model of heart failure.

Cristi L Galindo, Ehab Kasasbeh, Abigail Murphy, Sergey Ryzhov, Sean Lenihan, Farhaan A Ahmad, Philip Williams, Amy Nunnally, Jamie Adcock, Yanna Song and 10 more

Erratum issuedOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the American Heart Association, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 48 papers.

0numbers the graph read from it
0cells of the map it votes in
48citing papers in PubMed
7.3field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

48 citing papers in PubMed, 83 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. The case for neuregulin-1 as a clinical treatment for stroke.Frontiers in cellular neuroscience · 2024
    Review
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Review
  19. Pathomechanisms and therapeutic opportunities in radiation-induced heart disease: from bench to bedside.Clinical research in cardiology : official journal of the German Cardiac Society · 2021
    Review
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors at 3 institutions in 1 country.

Cristi L GalindoDivision of Cardiovascular Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN (C.L.G., E.K., A.M., S.R., S.L., F.A.A., P.W., A.N., J.A., T.L.T., I.F., D.B.S.).
Ehab KasasbehDivision of Cardiovascular Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN (C.L.G., E.K., A.M., S.R., S.L., F.A.A., P.W., A.N., J.A., T.L.T., I.F., D.B.S.).
Abigail MurphyDivision of Cardiovascular Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN (C.L.G., E.K., A.M., S.R., S.L., F.A.A., P.W., A.N., J.A., T.L.T., I.F., D.B.S.).
Sergey RyzhovDivision of Cardiovascular Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN (C.L.G., E.K., A.M., S.R., S.L., F.A.A., P.W., A.N., J.A., T.L.T., I.F., D.B.S.).
Sean LenihanDivision of Cardiovascular Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN (C.L.G., E.K., A.M., S.R., S.L., F.A.A., P.W., A.N., J.A., T.L.T., I.F., D.B.S.).
Farhaan A AhmadDivision of Cardiovascular Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN (C.L.G., E.K., A.M., S.R., S.L., F.A.A., P.W., A.N., J.A., T.L.T., I.F., D.B.S.).
Philip WilliamsDivision of Cardiovascular Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN (C.L.G., E.K., A.M., S.R., S.L., F.A.A., P.W., A.N., J.A., T.L.T., I.F., D.B.S.).
Amy NunnallyDivision of Cardiovascular Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN (C.L.G., E.K., A.M., S.R., S.L., F.A.A., P.W., A.N., J.A., T.L.T., I.F., D.B.S.).
Jamie AdcockDivision of Cardiovascular Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN (C.L.G., E.K., A.M., S.R., S.L., F.A.A., P.W., A.N., J.A., T.L.T., I.F., D.B.S.).
Yanna SongDepartment of Biostatistics, Vanderbilt University, Nashville, TN (Y.S., F.E.H.).
Frank E HarrellDepartment of Biostatistics, Vanderbilt University, Nashville, TN (Y.S., F.E.H.).
Truc-Linh TranDivision of Cardiovascular Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN (C.L.G., E.K., A.M., S.R., S.L., F.A.A., P.W., A.N., J.A., T.L.T., I.F., D.B.S.).
Tom J ParryAcorda Therapeutics, Ardsley, NY (T.J.P., J.I., A.G., A.O.C.).
Jen IaciAcorda Therapeutics, Ardsley, NY (T.J.P., J.I., A.G., A.O.C.).
Anindita GangulyAcorda Therapeutics, Ardsley, NY (T.J.P., J.I., A.G., A.O.C.).
Igor FeoktistovDivision of Cardiovascular Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN (C.L.G., E.K., A.M., S.R., S.L., F.A.A., P.W., A.N., J.A., T.L.T., I.F., D.B.S.).
Matthew K StephensonIngram Cancer Center, Vanderbilt University, Nashville, TN (M.K.S.).
Anthony O CaggianoAcorda Therapeutics, Ardsley, NY (T.J.P., J.I., A.G., A.O.C.).
Douglas B SawyerDivision of Cardiovascular Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN (C.L.G., E.K., A.M., S.R., S.L., F.A.A., P.W., A.N., J.A., T.L.T., I.F., D.B.S.).
John H CleatorDepartment of Pharmacology, Vanderbilt University, Nashville, TN (J.H.C.).
Vanderbilt University Medical Center · USAcorda Therapeutics (United States) · USVanderbilt University · US

Funding

Optimizing Cardiovascular Stem Cells for Cardiac Repair and RegenerationU01HL100398 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI HATZOPOULOS, ANTONIS · 2009 to 2015
$8.0M
Training In Cardiovascular ResearchT32HL007411 · NHLBI · VANDERBILT UNIVERSITY · PI BECKMAN, JOSHUA A · 1985 to 2020
$7.2M
Recombinant Neuregulin for the treatment of Heart FailureP20HL101425 · NHLBI · VANDERBILT UNIVERSITY · PI BROWN, NANCY J., CAGGIANO, ANTHONY O · 2010 to 2011
$1.3M
The anti-fibrotic effects of neuregulin in the heartK01HL121045 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI GALINDO, CRISTI LARA · 2014 to 2018
$747k
NHLBI NIH HHS K01 HL121045NHLBI NIH HHS K01 HL121045-01NHLBI NIH HHS P20 HL101425NHLBI NIH HHS T32 HL007411NHLBI NIH HHS T32HL007411NHLBI NIH HHS U01 HL100398
6 · The paper itself

Abstract

backgroundNeuregulin-1β (NRG-1β) is a growth factor critical for cardiac development and repair with therapeutic potential for heart failure. We previously showed that the glial growth factor 2 (GGF2) isoform of NRG-1β improves cardiac function in rodents after myocardial infarction (MI), but its efficacy in a large animal model of cardiac injury has not been examined. We therefore sought to examine the effects of GGF2 on ventricular remodeling, cardiac function, and global transcription in post-MI swine, as well as potential mechanisms for anti-remodeling effects. METHODS AND

resultsMI was induced in anesthetized swine (n=23) by intracoronary balloon occlusion. At 1 week post-MI, survivors (n=13) received GGF2 treatment (intravenous, biweekly for 4 weeks; n=8) or were untreated (n=5). At 5 weeks post-MI, fractional shortening was higher (32.8% versus 25.3%, P=0.019), and left ventricular (LV) end-diastolic dimension lower (4.5 versus 5.3 cm, P=0.003) in GGF2-treated animals. Treatment altered expression of 528 genes, as measured by microarrays, including collagens, basal lamina components, and matricellular proteins. GGF2-treated pigs exhibited improvements in LV cardiomyocyte mitochondria and intercalated disk structures and showed less fibrosis, altered matrix structure, and fewer myofibroblasts (myoFbs), based on trichrome staining, electron microscopy, and immunostaining. In vitro experiments with isolated murine and rat cardiac fibroblasts demonstrate that NRG-1β reduces myoFbs, and suppresses TGFβ-induced phospho-SMAD3 as well as αSMA expression.

conclusionsThese results suggest that GGF2/NRG-1β prevents adverse remodeling after injury in part via anti-fibrotic effects in the heart.

Indexed as

ActinsAnimalsCells, CulturedDisease Models, AnimalDose-Response Relationship, DrugFibrosisGene Expression RegulationHeart FailureMaleMice, Inbred C57BLMyocardial ContractionMyocardiumMyofibroblastsNeuregulin-1PhosphorylationRats, Sprague-DawleyActinsNeuregulin-1Smad3 Proteinextracellular matrixfibroblastsfibrosismyocardial infarctionneuregulin

Identifiers

PMID25341890
PMCPMC4323814
OpenAlexW2133857547

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.